drugset
Drugs / Cirmtuzumab
last change Jul 2026 re-read 9 days ago

Cirmtuzumab

also known as zilovertamab · UC-961

Monoclonal antibody targets ROR1

Developed for
B-cell chronic lymphocytic leukemia · chronic lymphocytic leukemia/small lymphocytic lymphoma · mantle cell lymphoma · breast neoplasm · marginal zone lymphoma · prostate carcinoma
Investigated by
Oncternal Therapeutics, Inc · University of California, San Diego · Pharmacyclics LLC. · Barbara Parker, MD · California Institute for Regenerative Medicine (CIRM) · Thomas Kipps

Trials 7

today NCT05431179 · Ph 3 NCT05156905 · Ph 1 NCT04501939 · Ph 2 NCT02776917 · Ph 1 NCT03088878 · Ph 1/2 NCT02860676 · Ph 1 NCT02222688 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT05156905 Jun 2022 → Oct 2024 prostate carcinoma University of California, San Diego Terminated No outcome recorded
Phase 1 NCT02776917 Aug 2018 → Jul 2021 breast neoplasm Barbara Parker, MD Completed No outcome recorded
Phase 1 NCT02860676 Nov 2016 → Feb 2018 chronic lymphocytic leukemia/small lymphocytic lymphoma University of California, San Diego Completed No outcome recorded
Phase 1 NCT02222688 Aug 2014 → Oct 2017 B-cell chronic lymphocytic leukemia Thomas Kipps Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03088878 Jan 2018 → Sep 2024 chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma Oncternal Therapeutics, Inc Completed No outcome recorded
Phase 21 trial
Phase 2 NCT04501939 Aug 2020 → Jul 2026 overdue B-cell chronic lymphocytic leukemia University of California, San Diego Active not recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT05431179 Mar 2023 → Nov 2026 immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, mantle cell lymphoma Oncternal Therapeutics, Inc Withdrawn No outcome recorded Stop: Business

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Cirmtuzumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156905 ↗
5

NCT02860676 ↗

NCT02776917 ↗

NCT02222688 ↗

NCT04501939 ↗

NCT03088878 ↗
Known as UC-961 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297728 ↗
Known as zilovertamab “This is a Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab (INN:zilovertamab), when given in combination with ibrutinib in...” NCT03088878 ↗
1

NCT05431179 ↗
Action Inhibit “Cirmtuzumab is safe and effective at inhibiting tumor cell ROR1 signaling in patients with CLL.” PMID 29859176 ↗ Jun 2018
Modality Monoclonal antibody “Cirmtuzumab is a humanized monoclonal antibody (mAb) that targets ROR1, an oncoembryonic orphan receptor for Wnt5a found on cancer stem cells (CSCs).” PMID 29859176 ↗ Jun 2018
Route Intravenous “Cirmtuzumab 600 mg is administered intravenously” NCT02776917 ↗
Target ROR1 “Cirmtuzumab is a humanized monoclonal antibody (mAb) that targets ROR1, an oncoembryonic orphan receptor for Wnt5a found on cancer stem cells (CSCs).” PMID 29859176 ↗ Jun 2018